Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(8):580-582; doi:10.1093/jnci/djk162
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ellenberg, S. S.
Right arrow Articles by Sun, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ellenberg, S. S.
Right arrow Articles by Sun, W.
Related Collections
Right arrowEditorial about this Article
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

Adjuvant Therapy for Gastric Cancer: How Negative Results Can Help Patients

Susan S. Ellenberg, Weijing Sun

Affiliations of authors: University of Pennsylvania School of Medicine, Philadelphia, PA

Correspondence to: Susan S. Ellenberg, PhD, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 423 Guardian Dr, Philadelphia, PA 19104 (e-mail: sellenbe@mail.med.upenn.edu).

The first 150 words of the full text of this article appear below.

Debate about the benefits of chemotherapy as an adjunct to potentially curative surgery in patients with locally advanced gastric cancer has extended over the past several decades. There have been many negative studies, interspersed with a few positive ones; meta-analyses have suggested a small benefit of adjuvant therapy, but the widely varying regimens and populations of the studies included in these meta-analyses have limited their impact on this study design. Recently, however, two large randomized controlled studies in the United States and Europe have provided more persuasive evidence that adjunctive and/or neoadjuvant therapy can contribute to the elimination of micrometastatic and increased survival (1,2), but there remains substantial room for further improvement of outcomes.

In this issue of the Journal, Cascinu et al. (3) report on a study designed before the completion and reporting of the positive studies mentioned above. Their paper reprises a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Editorial about this Article

Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial
Stefano Cascinu, Roberto Labianca, Carlo Barone, Armando Santoro, Carlo Carnaghi, Alessandra Cassano, Giordano D. Beretta, Vincenzo Catalano, Oscar Bertetto, Sandro Barni, Luciano Frontini, Enrico Aitini, Silvia Rota, Valter Torri, and Irene Floriani
J Natl Cancer Inst 2007 99: 601-607. [Abstract] [Full Text] [PDF]

Related Articles in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 577. [Extract] [Full Text] [PDF]

Press Release: Study Finds No Survival Benefit for Gastric Cancer Patients Treated with More Intensive Chemotherapy
Liz Savage
J Natl Cancer Inst 2007 99: 577. [Extract] [Full Text]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
A. Wu and J. Ji
Adjuvant Chemotherapy for Gastric Cancer or Not: A Dilemma?
J Natl Cancer Inst, March 19, 2008; 100(6): 376 - 377.
[Full Text] [PDF]